Dana Hellmold

Fabrication and Modelling of a Reservoir-Based Drug Delivery System for Customizable Release

R. Adelung, M. Synowitz, S. Wulfinghoff, 2022, Pharmaceutics.

Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche

M. Synowitz, J. Held-Feindt, C. Kubelt, 2021, International journal of molecular sciences.

Establishment of a Rodent Glioblastoma Partial Resection Model for Chemotherapy by Local Drug Carriers—Sharing Experience

R. Adelung, M. Synowitz, R. Scherließ, 2023, Biomedicines.

Localized Drug Delivery Systems in High‐Grade Glioma Therapy—From Construction to Application

R. Adelung, M. Synowitz, F. Schütt, 2022, Advanced Therapeutics.

Sequential Treatment with Temozolomide Plus Naturally Derived AT101 as an Alternative Therapeutic Strategy: Insights into Chemoresistance Mechanisms of Surviving Glioblastoma Cells

R. Adelung, O. Janssen, S. Sebens, 2023, International journal of molecular sciences.

A biopolymeric mesh enriched with PLGA microparticles loaded with AT101 for localized glioblastoma treatment

M. Akbari, M. Synowitz, J. Held-Feindt, 2023, Biomedical materials.

Insights into Gene Regulation under Temozolomide-Promoted Cellular Dormancy and Its Connection to Stemness in Human Glioblastoma

D. Esser, M. Synowitz, J. Held-Feindt, 2023, Cells.

Nitrogen-15 dynamic nuclear polarization of nicotinamide derivatives in biocompatible solutions

R. Herges, J. Hövener, A. Pravdivtsev, 2023, Science advances.